Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma

Kosuke Toyoda, Yasunobu Abe, Mariko Tsuda, Shojiro Haji, Ilseung Choi, Youko Suehiro, Junichi Kiyasu, Koichi Ohshima, Naokuni Uike

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Primary effusion lymphoma (PEL) is a rare B-cell lymphoma, characterized by human herpes virus 8 (HHV8) infection and serous effusions without detectable tumor masses. However, cases with HHV8 unrelated PEL have also been reported, mainly in Japan, and these are referred to as PEL-like lymphoma (PEL-LL). We describe a 70-year-old man with cardiac comorbidity who developed PEL-LL with pleural effusion. The patient achieved a complete response (CR) after treatment with oral low-dose sobuzoxane and etoposide combined with rituximab. To date, the patient has been in CR for about 7 months without chemotherapy. PEL-LL reportedly has a better prognosis than PEL. Because PEL-LL is positive for CD20, unlike PEL, combination therapy including rituximab may be effective. PEL-LL mainly affects elderly people, so that further investigation of tolerable and effective regimens is required.

Original languageEnglish
Pages (from-to)815-819
Number of pages5
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology
Volume55
Issue number7
Publication statusPublished - Jul 1 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma'. Together they form a unique fingerprint.

Cite this